CBX-12 for platinum-resistant ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called CBX-12 for people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if CBX-12 can shrink tumors or slow the cancer down.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that is high-grade serous type.
- Your cancer no longer responds to platinum-based chemotherapy or came back within 6 months of your last platinum treatment.
- You have at least one tumor that can be measured on a scan.
- You are 18 years or older and able to do most daily activities on your own (ECOG score 0 or 1).
- Your liver, kidneys, blood, and lungs are working well enough, and you have no active HIV, hepatitis B, or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called OPB-101 for people with a type of ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and if it can help shrink or slow the cancer.
This trial tests a new cell therapy (GB-5267) for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. It requires multiple tumor biopsies and aims to see if the treatment can help when standard chemo stops working.
This trial tests a new drug called SYS6043 (which targets a protein called B7-H3 found on some cancer cells) for people with advanced ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum chemotherapy. It compares SYS6043 to standard treatments like paclitaxel or topotecan, and aims to see if it can shrink tumors or slow the cancer.
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.